Migraine trials recruiting in Connecticut

All Migraine trials nationally

Cities in Connecticut

Recruiting trials in Connecticut

• A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
  NCT07018713 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven, Stamford
• A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
  NCT07018700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven, Stamford
• A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
  NCT07674654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Waterbury
• A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
  NCT04965675 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Connecticut: New Haven, Stamford
• A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
  NCT05164172 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Connecticut: New Haven, Stamford
• A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
  NCT05897320 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Connecticut: Stamford
• A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
  NCT06625060 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Connecticut: Stamford
• A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
  NCT07645924 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Connecticut: Waterbury
• External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy
  NCT06788977 · Phase: Not specified · Ages: 18 Years to 44 Years · Sex: Female · Connecticut: Darien
• Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
  NCT04743141 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Connecticut: Cromwell, Stamford
• MMA Embolization for Refractory Chronic Migraine
  NCT06735833 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · Connecticut: Hartford
• Mechanistic Studies of Psilocybin in Headache Disorders
  NCT06464367 · Phase: Early Phase 1 · Ages: 21 Years to 70 Years · Sex: All (male and female) · Connecticut: West Haven
• Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
  NCT04748601 · Phase: Phase 4 · Ages: 6 Years to 11 Years · Sex: All (male and female) · Connecticut: Stamford
• Randomized Study in Children and Adolescents With Migraine: Acute Treatment
  NCT04649242 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Connecticut: Cromwell, Hartford, Stamford
• Study of EVO756 in Adults With Migraine
  NCT07616128 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · Connecticut: Stamford
• Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
  NCT05125302 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Connecticut: Stamford